| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Tang,Jin-Rong | Chairman | 3.21% | |
| Lin,Mao-Yuan | Vice Chairman | 0.50% | |
| Hou,Jia-Long | Director | 33.61% | YOU HE INVESTMENT CO., LTD. |
| Yang,Qing-Hua | Director | 33.61% | YOU HE INVESTMENT CO., LTD. |
| Cai,Gao-Zhong | Independent Director | 0.00% | |
| Chen,Ji-Ming | Independent Director | 0.00% | |
| Huang,Zhao-Yuan | Independent Director | 0.00% |
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 118,766 | 236,890 | 270,243 |
| Operating cost | 85,906 | 137,506 | 146,966 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 32,860 | 99,384 | 123,277 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 32,860 | 99,384 | 123,277 |
| Operating expenses | 222,684 | 387,988 | 272,229 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -189,824 | -288,604 | -148,952 |
| Non-operating income and expenses | 6,357 | 4,181 | 2,516 |
| Net profit (loss) before tax | -183,467 | -284,423 | -146,436 |
| Income tax expense (benefits) | 26 | 4,947 | 6,507 |
| Net profit (loss) of ongoing business for the current period | -183,493 | -289,370 | -152,943 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -183,493 | -289,370 | -152,943 |
| Other comprehensive profit (loss), net | 579 | 8,294 | 9,635 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -182,914 | -281,076 | -143,308 |
| Net profit (loss) attributable to owners of parent company | -183,493 | -289,370 | -152,943 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | -182,914 | -281,076 | -143,308 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | 0 | 0 |
| Basic earnings per share (yuan) | -1 | -2 | -1 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -142,655 | -277,294 | -145,936 |
| Net cash inflows (outflows) from investing activities | -2,160 | -141,365 | -3,198 |
| Net cash inflow (outflow) from financing activities | 325,141 | 51,165 | 390,720 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 577 | 8,040 | 10,028 |
| Increase (decrease) in cash and cash equivalents in the current period | 180,903 | -359,454 | 251,614 |
| Beginning balance of cash and cash equivalents | 85,777 | 445,231 | 193,617 |
| Ending balance of cash and cash equivalents | 266,680 | 85,777 | 445,231 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 294,773 | 135,671 | 530,606 |
| Non-current asset | 58,215 | 64,920 | 84,054 |
| Total asset | 352,988 | 200,591 | 614,660 |
| Current liability | 49,278 | 104,515 | 74,259 |
| Non-current liability | 9,638 | 12,709 | 17,657 |
| Total liability | 58,916 | 117,224 | 91,916 |
| share capital | 1,459,744 | 1,229,744 | 1,387,384 |
| Equity - secruity token | - | - | - |
| capital reserve | 168,134 | 20,397 | 242,915 |
| retained earning | -1,330,695 | -1,163,084 | -1,113,714 |
| Other equity | -3,111 | -3,690 | 6,159 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 294,072 | 83,367 | 522,744 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | 0 | 0 |
| Total Equity | 294,072 | 83,367 | 522,744 |
| Share capital awaiting retirement (unit: share) | - | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 2 | 0 | 3 |
| 標案名稱 | 機關名稱 | 決標日期 | 決標金額 | 是否得標 |
|---|---|---|---|---|
| 檢驗部試劑、採血管等耗材採購案 | 臺北市立聯合醫院 | 113/01/31 | 是 | |
| 112年度克肺癆結核菌感染診斷升級套組(試管)採購案 | 衛生福利部桃園醫院 | 113/01/16 | 1274000.0 | 是 |
| 「IRGA採血管及檢驗試劑」財物採購案 | 衛生福利部胸腔病院 | 112/09/07 | 6960000.0 | 是 |
| Concentrate of proteolytic enzymes enriched in bromelain powder and gel for gel 5g單價開口契約 | 臺北榮民總醫院 | 112/08/02 | 是 | |
| 「肺結核菌對照管等2項」二年期單價開口合約 | 臺中榮民總醫院 | 112/05/24 | 5376000.0 | 是 |
| 112年度克肺癆結核菌感染診斷升級套組(試劑)採購案 | 衛生福利部桃園醫院 | 112/05/23 | 1496000.0 | 是 |
| 潛伏性結核病感染採檢試管與試劑組採購案 | 衛生福利部彰化醫院 | 112/05/04 | 1250000.0 | 是 |
| 優必士得新佛特注射劑4% (或同等品)等3項 | 國防醫學院 | 112/03/16 | 1727712.0 | 是 |
| 111-113年度檢驗試劑及耗材 | 國立成功大學醫學院附設醫院 | 112/02/21 | 4592500.0 | 是 |
| 111年潛伏結核感染診斷檢測套組第2次後續擴充案 | 衛生福利部疾病管制署 | 111/12/09 | 2610720.0 | 是 |
| 結核菌感染診斷升級套組等2項二年單價開口契約 | 臺北榮民總醫院 | 111/11/15 | 3136000.0 | 是 |
| 111年潛伏結核感染診斷檢測套組第1次後續擴充案 | 衛生福利部疾病管制署 | 111/10/12 | 1237005.0 | 是 |
| 微生物科用試劑2項(開口契約) | 高雄榮民總醫院 | 111/04/27 | 4435200.0 | 是 |
| 111年潛伏結核感染診斷檢測套組 | 衛生福利部疾病管制署 | 111/03/02 | 59393250.0 | 是 |
| 110年潛伏結核感染診斷檢測套組，第3次後續擴充 | 衛生福利部疾病管制署 | 110/12/21 | 5537994.0 | 是 |
| 結核菌試管試劑組計2項 | 高雄榮民總醫院 | 110/11/26 | 264000.0 | 是 |
| 110年潛伏結核感染診斷檢測套組，第2次後續擴充 | 衛生福利部疾病管制署 | 110/11/18 | 1361556.0 | 是 |
| 110年潛伏結核感染診斷檢測套組，第1次後續擴充 | 衛生福利部疾病管制署 | 110/10/15 | 3529960.0 | 是 |
| 110年度「衛材名稱：克肺癆 結核菌感染診斷升級套組(試劑、試管)採購案 | 衛生福利部桃園醫院 | 110/06/29 | 912000.0 | 是 |
| 潛伏性結核病感染採撿試管與試劑組採購案 | 衛生福利部彰化醫院 | 110/06/29 | 884700.0 | 是 |
| 「肺結核菌對照管等7項」二年期單價開口合約 | 臺中榮民總醫院 | 110/06/04 | 2240000.0 | 是 |
| 110年潛伏結核感染診斷檢測套組 | 衛生福利部疾病管制署 | 110/02/09 | 36495936.0 | 是 |
| 109年肺結核輔助診斷檢測套組採購案第一次後續擴充 | 衛生福利部疾病管制署 | 109/10/30 | 3558450.0 | 是 |
| 結核菌感染診斷升級套組等2項二年單價開口契約 | 臺北榮民總醫院 | 109/10/29 | 3200000.0 | 是 |
| 109年度「衛材名稱：丙型干擾素試劑、採血管)採購案 | 衛生福利部桃園醫院 | 109/10/28 | 387600.0 | 是 |
| 結核菌感染診斷專用試管組等3項單價開口契約 | 臺北榮民總醫院 | 109/09/30 | 781200.0 | 是 |
| 109年肺結核輔助診斷檢測套組 | 衛生福利部疾病管制署 | 109/07/07 | 28683750.0 | 是 |
| 109年結核病輔助診斷檢驗套組(QFT-GIT)採購案 | 彰化縣衛生局 | 109/05/05 | 2739000.0 | 是 |
| 108年肺結核輔助診斷檢測套組後續擴充 | 衛生福利部疾病管制署 | 108/11/25 | 18547460.0 | 是 |
| 108年肺結核輔助診斷檢測套組採購案 | 衛生福利部疾病管制署 | 108/06/24 | 57949700.0 | 是 |
| 108年結核病輔助診斷檢驗套組(QFT-GIT)採購案 | 彰化縣衛生局 | 108/04/11 | 2739000.0 | 是 |
| 肺結核診斷試管組等2項二年期單價合約 | 臺中榮民總醫院 | 107/12/25 | 1140000.0 | 是 |
| 107年度「衛材名稱：丙型干擾素試劑、採血管)採購案 | 衛生福利部桃園醫院 | 107/10/23 | 387600.0 | 是 |
| 微生物科用試劑2項 | 高雄榮民總醫院 | 107/06/27 | 3000000.0 | 是 |
| 107年結核病輔助診斷檢驗套組(QFT-GIT)採購案 | 彰化縣衛生局 | 107/04/17 | 2554200.0 | 是 |
| 結核菌感染診斷專用試管組等3項兩年單價開口合約 | 臺北榮民總醫院 | 107/02/22 | 558000.0 | 是 |
| 彰化縣衛生局「106年結核病輔助診斷檢驗套組(QFT-GIT)採購案」 | 彰化縣衛生局 | 106/09/19 | 619200.0 | 是 |
| 丙型干擾素血液測驗檢驗試劑 | 衛生福利部胸腔病院 | 106/04/26 | 292000.0 | 是 |
| 「檢驗試劑等6項試劑」貳年期單價合 | 臺中榮民總醫院 | 105/12/08 | 2280000.0 | 是 |
| 彰化縣衛生局「105年結核病輔助診斷檢驗套組(QFT-GIT)採購案」 | 彰化縣衛生局 | 105/11/24 | 387000.0 | 是 |
| 結核菌感染診斷試劑組等2項 | 國防部軍醫局 | 105/08/02 | 364000.0 | 是 |
| 結核菌感染診斷專用試管組等3項2年單價開口合約 | 臺北榮民總醫院 | 105/02/04 | 2901600.0 | 是 |
| 104年結核病輔助診斷檢驗套組(QFT-GIT)採購案 | 彰化縣衛生局 | 104/02/05 | 2880000.0 | 是 |
| 『肺結核菌感染診斷試管組及試劑組等 2項』 2年期單價合約 | 臺中榮民總醫院 | 103/12/17 | 2880000.0 | 是 |
| 結核病輔助診斷檢驗套組(QFT-GIT)採購案 | 衛生福利部疾病管制署 | 103/09/04 | 3420000.0 | 是 |
| 臺東縣衛生局--QFT-GIT(QuantiFERON GOLD in Tube)檢驗試劑 | 臺東縣政府 | 103/07/03 | 754600.0 | 是 |
| 克肺癆結核菌感染診斷試管組等一批開口契約 | 財團法人國家衛生研究院 | 103/06/11 | 2212096.0 | 是 |
| 結核菌感染診斷試劑等2項 | 國防部軍醫局 | 103/05/13 | 468000.0 | 是 |
| 結核菌感染診斷專用試管等3項2年單價開口合約 | 臺北榮民總醫院 | 102/12/25 | 4062240.0 | 是 |
| TB抗原、Nil對照及Mitogen對照採血管等一批 | 國家衛生研究院 | 102/05/16 | 2500000.0 | 是 |
